• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25150 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, clinical and cost-effectiveness of neonatal screening for type 1 citrullinaemia, trifunctional protein deficiency, holocarboxyl synthetase deficiency, argininosuccinic aciduria and 3-methylcrotonyl-CoA carboxylase deficiency]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Telemedicine for the follow-up of post-stroke patients]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Artificial intelligence software to detect viable tissue in stroke patients on CT or perfusion MRI of the skull]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Neurosurgical robot for electrode implantation, brain biopsies and spinal surgery]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of model-informed precision dosing of biologic agents]
2026     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of modifications to the BreastCheck programme. Workstream 1 (of 2): consideration of screening pathways that incorporate breast density
2026     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Evaluation of injectable type I collagen in AMIC/ACIC arthroscopic applications]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Neuromodulator medical device for the treatment of opioid use disorder]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Virtual reality for the treatment of chronic pain]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of pelvic floor training during pregnancy for the prevention of pre and postnatal urinary incontinence]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Laboratory animals – farm animals: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Flour: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pets-rodents: Evidence report for the S3 guideline on allergic rhinitis]
2026     NIHR Health Services and Delivery Research programme Implementing artificial intelligence in chest diagnostics for lung disease: a mixed-methods evaluation
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pollen: Evidence report for the S3 guideline on allergic rhinitis]
2026     NIHR Health Technology Assessment programme Diagnostic tools to establish the presence and severity of peripheral arterial disease in people with diabetes: a synopsis of the DM PAD prospective multicentre diagnostic accuracy study
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [House dust mites: Evidence report for the S3 guideline on allergic rhinitis]
2026     Health Information and Quality Authority (HIQA) Scalable training and knowledge exchange on guideline development for patients, public, and healthcare professionals (The STAKEholder Project)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Test quality: Evidence report for the S3 guideline on allergic rhinitis]
2026     NIHR Health Technology Assessment programme Relative and bedside nurse assessment of comfort and communication during propofol, dexmedetomidine, or clonidine-based sedation: pre-planned analysis within the A2B RCT
2026     NIHR Health Technology Assessment programme Understanding barriers and facilitators of implementing a new assessment and bridging tool to support those at risk of repeat self-harm in prison: the qualitative RAPPS study
2026     NIHR Health Technology Assessment programme Validating and updating the OHTS-EGPS model predicting 5-year glaucoma risk among patients with ocular hypertension using electronic medical records: a cohort study
2026     NIHR Health Services and Delivery Research programme A randomised feasibility trial of an intervention involving mental health support workers as link workers to improve dental visiting in people with severe mental illness: The Mouth Matters in Mental Health Study
2026     NIHR Health Services and Delivery Research programme The use of restrictive practices in the everyday care of people living with dementia in hospital settings: an ethnographic study
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Chronic obstructive pulmonary disease (COPD)]
2026     NIHR Health Technology Assessment programme Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Local hyperbaric oxygen therapy for diabetic foot ulcers]
2026     NIHR Health Technology Assessment programme Timing of birth to improve outcomes in chronic or gestational hypertension: the WILL RCT
2026     HTA South [Biomarkers as support in decision-making for computed tomography in mild head injury in adults – a systematic review and assessment of medical, economical and ethical aspects]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fundus photography for the diagnosis of diabetic retinopathy]
2026     NIHR Health Technology Assessment programme Reducing self-harm in adolescents: the RISA-IPD comprehensive synopsis
2026     NIHR Health Technology Assessment programme Home-based extended rehabilitation for older people with frailty (HERO): a multicentre randomised controlled trial with health economic analysis and process evaluation
2026     NIHR Health Services and Delivery Research programme Models of perinatal care for women using drugs and their infants: synopsis of The Stepping Stones Study
2026     NIHR Health Services and Delivery Research programme Intervening to eliminate the centre-effect variation in home dialysis use: a synopsis of Inter-CEPt, an exploratory sequential mixed-methods study
2026     NIHR Health Technology Assessment programme Clinical utility of biomarkers for outcomes prediction in adults with suspected sepsis presenting to the emergency department: a synthesis of current evidence
2026     NIHR Health Technology Assessment programme Effectiveness and cost-effectiveness of targeted and population screening for osteoporosis in women: scoping review
2026     Health Information and Quality Authority (HIQA) Health technology assessment of extending BowelScreen to those aged 50 to 54 years
2026     NIHR Health Technology Assessment programme Interventions to safely and effectively reduce (taper) use of opioids in chronic non-cancer pain: a systematic review
2026     NIHR Health Technology Assessment programme Comparing the clinical and cost-effectiveness of various washout policies in preventing catheter associated complications in adults living with long-term catheters: synopsis of the CATHETER II RCT
2026     Scottish Health Technologies Group (SHTG) Surface guided radiation therapy (SGRT)
2026     National Institute for Health and Care Excellence (NICE) Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause. NICE technology appraisal guidance 1143
2026     National Institute for Health and Care Excellence (NICE) Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils. NICE technology appraisal guidance 1142
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radiofrequency energy treatment for organic erectile dysfunction]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Economic evaluation of a booster dose of Tdap vaccine in adolescents]
2026     National Institute for Health and Care Excellence (NICE) Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over. NICE technology appraisal guidance 1140
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety, clinical effectiveness, and cost-effectiveness of neonatal screening for beta-ketothiolase deficiency and classic galactosemia. Update]
2026     National Institute for Health and Care Excellence (NICE) Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal). NICE technology appraisal guidance 1141
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Exercise programs for cancer patients over 65 years of age undergoing chemotherapy. Systematic review]
2026     National Institute for Health and Care Excellence (NICE) Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment. NICE technology appraisal guidance 1139
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of endovascular treatment using transarterial radioembolization for intermediate and advanced hepatocellular carcinoma]
2026     National Institute for Health and Care Excellence (NICE) Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer. NICE technology appraisal guidance 1138
2026     National Institute for Health and Care Excellence (NICE) Pegzilarginase for treating arginase-1 deficiency in people 2 years and over. NICE highly specialised technologies guidance 35
2026     National Institute for Health and Care Excellence (NICE) Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock. NICE HealthTech guidance 774
2026     National Institute for Health and Care Excellence (NICE) Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock. NICE HealthTech guidance 775
2026     National Institute for Health and Care Excellence (NICE) Givinostat for treating Duchenne muscular dystrophy in people 6 years and over. NICE technology appraisal guidance 1157
2026     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to help detect or characterise colorectal polyps. NICE HealthTech guidance 773
2026     National Institute for Health and Care Excellence (NICE) Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1158
2026     NIHR Health Technology Assessment programme Methods and mechanisms for measuring and monitoring outcomes from newborn bloodspot screening: a scoping review
2026     National Institute for Health and Care Excellence (NICE) Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation. NICE HealthTech guidance 772
2026     National Institute for Health and Care Excellence (NICE) Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy. NICE technology appraisal guidance 1156
2026     Scottish Health Technologies Group (SHTG) Wearable home-testing devices for diagnosing obstructive sleep apnoea syndrome (OSAHS)
2026     National Institute for Health and Care Excellence (NICE) Rozanolixizumab for treating antibody-positive generalised myasthenia gravis. NICE technology appraisal guidance 1155
2026     Scottish Health Technologies Group (SHTG) Out-of-hospital cardiac arrest (OHCA)
2026     National Institute for Health and Care Excellence (NICE) Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity. NICE technology appraisal guidance 1152
2026     Scottish Health Technologies Group (SHTG) Robotic assisted bronchoscopy (RAB)
2026     National Institute for Health and Care Excellence (NICE) Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment. NICE technology appraisal guidance 1153
2026     Scottish Health Technologies Group (SHTG) Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (OSAHS)
2026     National Institute for Health and Care Excellence (NICE) Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal). NICE technology appraisal guidance 1154
2026     Scottish Health Technologies Group (SHTG) Computed tomography fractional flow rate (CT-FFR)
2026     National Institute for Health and Care Excellence (NICE) Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1150
2026     Scottish Health Technologies Group (SHTG) Specialist interventions for managing chronic non-malignant pain in adults
2026     National Institute for Health and Care Excellence (NICE) Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal). NICE technology appraisal guidance 1151
2026     Scottish Health Technologies Group (SHTG) Surgical care practitioners
2026     National Institute for Health and Care Excellence (NICE) Digital technologies to support self-management of asthma: early-use assessment. NICE HealthTech guidance 778
2026     NIHR Health Services and Delivery Research programme Referral pathways into the NHS Digital Weight Management Programme for musculoskeletal and perioperative patients: rapid process evaluation
2026     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment. NICE HealthTech guidance 779
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for prostate cancer]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the regulations governing a tiered system of emergency structures in hospitals]
2026     NIHR Health Technology Assessment programme Addition of early vocational advice to usual primary care on sickness absence in employed adults: exploratory findings from the discontinued WAVE Randomised Controlled Trial
2026     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of medical management versus surgery for deep infiltrating endometriosis: synopsis from the DIAMOND RCT
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Immunological assays of tacrolimus and cyclosporine]
2026     Andalusian Health Technology Assessment Area (AETSA) [Assessment of body composition and muscular functionality in the oncology patient. Systematic review]
2026     National Institute for Health and Care Excellence (NICE) Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy. NICE technology appraisal guidance 1126
2026     NIHR Health Services and Delivery Research programme Independence and interdependence of non-medical practitioners in the emergency care skill-mix (SKILLMix-ED): a multi-method study to develop a measurement tool
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Relevance of intraperitoneal chemotherapy for preventing or treating neoplasms of the peritoneal surfaces - peritoneal metastases secondary to colorectal cancer]
2026     National Institute for Health and Care Excellence (NICE) Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal). NICE technology appraisal guidance 1124
2026     NIHR Health Services and Delivery Research programme Accounting for needs in geographical health care resource allocation
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Robotic surgery – relevance and optimal framework for three oncological indications: total hysterectomy for endometrial cancer, radical prostatectomy for prostate cancer, and partial nephrectomy for renal cancer]
2026     National Institute for Health and Care Excellence (NICE) Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal). NICE technology appraisal guidance 1125
2026     NIHR Health Services and Delivery Research programme Lifeguard Pharmacy - A feasibility trial of a novel pharmacy-based intervention for people experiencing domestic abuse and/or suicidal ideation
2026     NIHR Health Services and Delivery Research programme Developing the evidence and associated service models to improve pain management in older people living with frailty: a synopsis of the POPPY mixed method, co-design study
2026     National Institute for Health and Care Excellence (NICE) Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal). NICE technology appraisal guidance 1123
2026     NIHR Health Technology Assessment programme Development and description of Early Stroke Specialist Vocational Rehabilitation delivered in the RETAKE trial
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [The integration of care and services for the benefit of vulnerable populations]
2026     NIHR Health Technology Assessment programme Prevention and treatment of incontinence-associated dermatitis through optimising care: the PREVENT-IAD Synopsis
2026     National Institute for Health and Care Excellence (NICE) Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1122
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Teprotumumab (TEPEZZA)]
2026     National Institute for Health and Care Excellence (NICE) Acoramidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 1121
2026     NIHR Health Services and Delivery Research programme Evidence base to inform health service configuration for abortion provision: the SACHA (Shaping Abortion for Change) multi-component study
2026     Austrian Institute for Health Technology Assessment (AIHTA) Artificial intelligence for hospital documentation support - a scoping review of current use cases